An experimental pill from AstraZeneca has shown a 56% reduction in the risk of breast cancer progression, according to a study presented at ASCO

Administration of AstraZeneca's experimental pill camizestrant to breast cancer patients at the first sign of resistance to standard therapies cut the risk of disease progression or death in half, according to results presented Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago. 

Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care, said this early approach reduced the risk of disease progression or death by 56%.